Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2014

View Archived Issues

Amarantus and Washington University School of Medicine collaborate in Wolfram syndrome

Servier and miRagen extend microRNA-targeting drug collaboration

BioLineRx in-licenses compound for neuropathic pain

Galectin Therapeutics reports preclinical data for GR-MD-02 from mouse model of NASH

Questcor Pharmaceuticals to acquire rights to Synacthen and Synacthen Depot

Discovery and characterization of novel broad-spectrum antibacterial agents

Phase I data for selective inhibitor of ACAT-1 in adrenocortical carcinoma

Safety and efficacy data reported for VRS-317, a novel long-acting rhGH

Testosterone levels increased for over 28 days in healthy men by lasofoxifene

A modified activin B propeptide to reverse activin-induced muscle wasting

Karyopharm's selinexor enters phase II trial in acute myeloid leukemia

Coherus' etanercept biosimilar enters phase III trial in rheumatoid arthritis

Auspex reports results from SD-809 switching study in Huntington's disease

Merck & Co. reports discovery of OX2 receptor antagonists

Chinese company discloses new cancer treatment

Lumacaftor/ivacaftor achieves endpoints in phase III cystic fibrosis trials

Sunshine Lake Pharma synthesizes novel HCV NS5A inhibitors

Novel FFA1 receptor agonists reported in Boehringer Ingelheim patent

French group details novel Na+/I- cotransporter inhibitors

Bionomics and Merck & Co. collaborate to develop BNC-375 for cognitive dysfunction

Catch-up growth seen with weekly injection of Lagova in phase II study

FDA advisory committee votes against accelerated approval of olaparib for ovarian cancer

Sobi files for E.U. approval of Xiapex for Peyronie's disease

Lundbeck completes acquisition of Chelsea Therapeutics

EMA accepts Ravicti MAA

FDA accepts Merck & Co.'s NDA for fixed-dose raltegravir and lamivudine

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...